Patents Assigned to Genentech
  • Patent number: 9550777
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 24, 2017
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • Publication number: 20170015755
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicant: Genentech, Inc.
    Inventors: Kevin WALSH, Patricia DE ALMEIDA, Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, James ANDYA, Ye SHEN
  • Publication number: 20170015678
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 19, 2017
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Publication number: 20170015627
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: July 28, 2016
    Publication date: January 19, 2017
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 9546164
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: January 17, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu
  • Patent number: 9546178
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 17, 2017
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • Patent number: 9546182
    Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 17, 2017
    Assignee: Genentech, Inc.
    Inventors: Jennafer Dotson, Robert Andrew Heald, Timothy Heffron, Graham Elgin Jones, Sussie Lerche Krintel, Neville James McLean, Chudi Ndubaku, Alan G. Olivero, Laurent Salphati, Lan Wang, BinQuing Wei
  • Publication number: 20170009015
    Abstract: Provided herein are methods of preparing a poloxamer for use in a cell culture medium. Also provided herein are cell culture media containing the poloxamer prepared by the methods herein, as well as methods of using the media for cell culturing and polypeptide production from cells.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 12, 2017
    Applicant: Genentech, Inc.
    Inventors: Ganesh Prasadh VISSVESVARAN, Robert David KISS, Steven J. MEIER, Inchan KWON, Kara CALHOUN, Kate WINCHESTER, Amelia ADAMS, Marion GLENN, Stefan KOENIG, Alan DEESE
  • Publication number: 20170008971
    Abstract: The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 12, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark S. DENNIS, Allen EBENS, Bryan IRVING, Teemu T. JUNTTILA, Ji LI
  • Publication number: 20170008877
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 12, 2017
    Applicant: Genentech, Inc.
    Inventors: Snahel PATEL, Gregory HAMILTON, Craig Stivala, Huifen Chen, Guiling Zhao
  • Patent number: 9539251
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 10, 2017
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • Patent number: 9539263
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: January 10, 2017
    Assignees: Genentech, Inc., Hoffmann-La Roche, Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
  • Publication number: 20170002017
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: February 5, 2016
    Publication date: January 5, 2017
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • Publication number: 20170000885
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
    Type: Application
    Filed: June 7, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • Publication number: 20170001990
    Abstract: The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Jinhua CHEN, Charles Z. DING, Peter DRAGOVICH, Benjamin FAUBER, Zhenting GAO, Sharada S. LABADIE, Kwong Wah LAI, Hans Edward PURKEY, Kirk ROBARGE, Binqing WEI, Aihe ZHOU
  • Publication number: 20170002085
    Abstract: Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.
    Type: Application
    Filed: March 15, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: FREDERIC J. DE SAUVAGE, BRIAN BIEHS
  • Publication number: 20170002074
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 5, 2017
    Applicant: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Publication number: 20170002022
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Publication number: 20170002086
    Abstract: The invention provides immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 14, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Peter Dragovich, Thomas Harden Pillow, Shang-Fan Yu
  • Publication number: 20170001997
    Abstract: Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Jason BURCH, Huifen CHEN, Xiaojing WANG